title: Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
authors.affiliation: First Department of Internal Medicine, Gifu University Graduate School of Medicine , Gifu , Japan.
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nakamura
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanemura
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shibata
authors.forename: Takuro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Ryoko
authors.initials: R
authors.lastname: Mabuchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitagawa
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide